Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Temozolomide + Zotiraciclib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Zotiraciclib | SB1317|TG02 | CDK1 Inhibitor 13 CDK2 Inhibitor 31 CDK5 Inhibitor 8 CDK7 Inhibitor 16 CDK9 Inhibitor 21 FLT3 Inhibitor 69 JAK2 Inhibitor 19 | Zotiraciclib (TG02) is a pyrimidine-based molecule that inhibits CDK1, CDK2, CDK3, CDK5, CDK7, CDK9, JAK2, and FLT3, which results in growth inhibition in tumor cells (PMID: 21860433). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02942264 | Phase Ib/II | Zotiraciclib Temozolomide + Zotiraciclib | TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | Completed | USA | 0 |
NCT03224104 | Phase I | Radiotherapy + Zotiraciclib Temozolomide + Zotiraciclib Zotiraciclib | Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM) | Completed | NLD | FRA | DEU | CHE | AUT | 0 |